Partnering with JCR
Together We Soar.
We will continuously try to create value by our unique technology platform such as J-Brain Cargo® toward our corporate philosophy: “contributing towards people’s healthcare through pharmaceutical products.”
In addition to the in-house research activities, we think collaborative research and development work with other companies are also important. The values of our technology platform will be increased by integrating our technologies and other technologies and by implementing our technology in other companies’ products. We aim at “research-oriented specialty pharma with global exposure” utilizing collaborative research and development work.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. Our core values – reliability, confidence, and belief – means that the work we do benefits all our stakeholders, including employees, partners, and patients.
We continue to build upon our 46-year legacy in Japan while expanding our global footprint with trials in the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. If you are interested in speaking with JCR regarding business development opportunities, email email@example.com.
We Stand with Patients
At JCR, we are united with the patients, families, and communities we serve. We seek to understand their needs and develop new medicines with significant and meaningful benefits. We created JCR to improve the lives of people with rare and genetic diseases, and we remain driven by this common purpose.
We recognize the limitations of available therapies for rare and genetic diseases, including lysosomal storage disorders such as MPS Type I, MPS Type II, and MPS Type III. Many people with these conditions experience severe complications of the central nervous system (CNS). Developmental delays, impaired cognition, and an overall poor prognosis can negatively impact independence and quality of life for both patients and caregivers.
Together, we are working towards better outcomes for patients.
We continue to build upon our history of success in Japan while expanding our global footprint by developing first-in-class and best-in-class therapies, and further expanding our capabilities in manufacturing and R&D.
Recent News Milestones
Received Orphan Drug Designation for JR-141 (MPS II) in Japan
Filed for marketing approval of JR-141 (MPS II) in Japan
|October 2020||First patient dosed in phase 1/2 of global clinical trial of JR-171 (MPS I)|
|December 2020||Filed for marketing authorization of JR-141 (MPS II) in Brazil|
|May 2021||Launch of pabinafusp alfa (MPS II) in Japan|
|October 2021||Received PRIME Designation for JR-141 (MPS II) from EMA|
|January 2022||Received Orphan Drug Designation for JR-441 from FDA|
View our WORLDSymposium 2022 Abstracts
This year, JCR Pharmaceuticals is attending the virtual 18th annual WORLDSymposium, an annual conference dedicated to lysosomal storage disorders, Feb. 7-11. We will have six presentations at the event.
J-Brain Cargo® Technology
Our first-in-class proprietary technology, J-Brain Cargo®, enables us to develop therapies that cross the blood-brain barrier and penetrate the central nervous system (CNS). The CNS complications of diseases are often severe, resulting in developmental delays, an impact on cognition and, above all, poor prognosis, which affect patients’ independence as well as the quality of life of patients and their caregivers. With J-Brain Cargo®, we seek to address the unresolved clinical challenges of lysosomal storage disorders by delivering the enzyme to both the body and the brain.